Pangaea Oncology Valuation

Is PANG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PANG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PANG's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PANG's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PANG?

Key metric: As PANG is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for PANG. This is calculated by dividing PANG's market cap by their current revenue.
What is PANG's PS Ratio?
PS Ratio	4.2x
Sales	€14.35m
Market Cap	€60.98m

PANG key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.4x
Enterprise Value/EBITDA	-24x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does PANG's PS Ratio compare to its peers?

The above table shows the PS ratio for PANG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3.6x
EEP Euroespes	1x	n/a	€3.7m
ORY Oryzon Genomics	6.4x	61.7%	€98.1m
BST Biotechnology Assets	6.5x	n/a	€21.0m
RJF Laboratorio Reig Jofre	0.7x	8.7%	€225.8m
PANG Pangaea Oncology	4.2x	4.4%	€61.0m

Price-To-Sales vs Peers: PANG is expensive based on its Price-To-Sales Ratio (4.2x) compared to the peer average (3.6x).

Price to Sales Ratio vs Industry

How does PANG's PS Ratio compare vs other companies in the European Life Sciences Industry?

5 Companies	Price / Sales	Estimated Growth	Market Cap

5 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: PANG is expensive based on its Price-To-Sales Ratio (4.2x) compared to the European Life Sciences industry average (4.2x).

Price to Sales Ratio vs Fair Ratio

What is PANG's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PANG PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	4.2x
Fair PS Ratio	0.9x

Price-To-Sales vs Fair Ratio: PANG is expensive based on its Price-To-Sales Ratio (4.2x) compared to the estimated Fair Price-To-Sales Ratio (0.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.